Previous 10 | Next 10 |
Kiromic BioPharma (KRBP): FY GAAP EPS of -$4.42.Cash and equivalents were $10,150,500 as of December 31, 2020, compared to $1,929,100 as of December 31, 2019.Press Release For further details see: Kiromic BioPharma reports FY results
Completion of $15 million IPO Longwood University Licensing Agreement of chPD1 Two IND Application Filings for chPD1, Isomesothelin, Allogeneic Gamma Delta, CAR-T Therapies GMP Facility Completion, Certification Kiromic BioPharma (NASDAQ: ...
Kiromic BioPharma, Inc. (Nasdaq: KRBP ) is an immuno-oncology target discovery and gene-editing company with a proprietary artificial intelligence neural network platform (Diamond AI) to develop novel oncology therapeutics. Today, the Company announced an interview with the ...
Kiromic Biopharma, Inc. (Nasdaq: KRBP), a target discovery and gene-editing company utilizing artificial intelligence and its proprietary neural network platform with a therapeutic focus on immuno-oncology, announced today the planned resubmission of two investigational new drug (IND) a...
Kiromic BioPharma (KRBP) has announced the completion of the chPD1 licensing agreement with Longwood University. The shares are trading ~17.0% higher in the post-market.The traditional PD-1 inhibitors block the PD-1 receptor, “removing the brakes” of T-cell a...
Kiromic BioPharma, Inc. (Nasdaq: KRBP), an immuno-oncology target discovery and gene-editing company, with a proprietary artificial intelligence neural network platform (Diamond AI) to develop novel oncology therapeutics, has announced the completion of the chPD1 licensing agreement wit...
Kiromic BioPharma, Inc. (Nasdaq: KRBP), an immuno-oncology target discovery and gene-editing company, with a proprietary artificial intelligence neural network platform (Diamond AI) to develop novel oncology therapeutics, has announced the completion and certification of its GMP facilit...
Kiromic Biopharma, Inc. (Nasdaq: KRBP), a target discovery and gene-editing company utilizing artificial intelligence and proprietary neural network platform with a therapeutic focus on immuno-oncology, announces the filing of key European patents for its chimeric PD-1 (chPD1) target. ...
Nano-cap Kiromic BioPharma ([[KRBP]] +6.8%) has announced the submission of two investigational new drug ((IND)) applications with the FDA for the initiation of two separate Phase 1 trials of an allogenic CAR-T administered intravenously and intrapleural/intraperitoneal for the treatment...
Kiromic BioPharma (“the Company”) (NASDAQ: KRBP) , a target discovery and gene-editing company utilizing artificial intelligence and its proprietary neural network platform with a therapeutic focus on immuno-oncology, announced today the submission of two investigation...
News, Short Squeeze, Breakout and More Instantly...
Kiromic BioPharma Inc. Company Name:
KRBP Stock Symbol:
NASDAQ Market:
Kiromic BioPharma Inc. Website:
Enrollment in the Expansion Phase Expected to Commence in September Deltacel Safety Confirmed at Day 30 in Trial’s Fifth Patient; Efficacy Results on this Patient Expected in August Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company...
Follow-up Findings Show Stable Disease FDA and IRB Approve IND for a Single-Use, Single-Patient Treatment with Deltacel Fast Track Designation Request Submitted to FDA Complete Enrollment in Trial’s Second Cohort Expected in July Kiromic BioPharma, Inc. ...
Favorable Follow-up Findings Include Stable Disease and a 13% Decrease in Tumor Size Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable six-month follow-up results from the first patient enrolled in the Deltacel-01 Phase ...